{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:55Z","timestamp":1787026615848,"version":"build-2736575974"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018628","name":"Scientific Research Foundation of Education Department of Anhui Province of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are extensively utilized in the treatment of oncological patients, and the immune-related adverse reactions they induce merit close monitoring. This report describes a case of a lung cancer patient who, after receiving chemotherapy in combination with the programmed death-1 (PD-1) inhibitor sintilimab, presented with systemic fatigue, alterations in mental and behavioral patterns, somnolence, and symptoms of diabetes insipidus, leading to a diagnosis of grade 4 immune-related hypophysitis. The patient experienced symptomatic relief following pulse therapy with dexamethasone sodium phosphate injections (30mg every 12 hours), and was subsequently treated with prednisone acetate tablets (30 mg\/day), which were gradually reduced to a physiological replacement dose. The treatment with sintilimab was discontinued, and the patient\u2019s symptoms gradually improved, with normalization of urine output.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1534179","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T01:56:58Z","timestamp":1737597418000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ming-xing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.05.002","article-title":"A novel etiology of hypophysitis: immune checkpoint inhibitors","volume":"49","author":"Fernandes","year":"2020","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1400841","article-title":"Differences in checkpoint-inhibitor-induced hypophysitis: mono- versus combination therapy induced hypophysitis","volume":"15","author":"Van der Leij","year":"2024","journal-title":"Front endocrinology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin endocrinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2174\/1871530323666221208111823","article-title":"Immunotherapy-associated hypophysitis under anti-PD1: two case reports","volume":"23","author":"Shen","year":"2023","journal-title":"Endocrine Metab Immune Disord Drug targets"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594558","article-title":"Sintilimab: A promising anti-tumor PD-1 antibody","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes endocrinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s40425-018-0477-9","article-title":"Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"6","author":"Zhou","year":"2018","journal-title":"J immunotherapy cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.tem.2019.06.004","article-title":"The changing clinical spectrum of hypophysitis","volume":"30","author":"Chiloiro","year":"2019","journal-title":"Trends Endocrinol metabolism: TEM"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1709344","article-title":"Immune checkpoint inhibitors and endocrine side effects, a narrative review","volume":"132","author":"Agrawal","year":"2020","journal-title":"Postgraduate Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-019-01120-x","article-title":"Imaging findings in hypophysitis: a review","volume":"125","author":"Caranci","year":"2020","journal-title":"La Radiologia medica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4137\/cmed.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol diabetes"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000506903","article-title":"Hypophysitis (Including igG4 and immunotherapy)","volume":"110","author":"Angelousi","year":"2020","journal-title":"Neuroendocrinology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12957-023-03194-4","article-title":"Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review","volume":"21","author":"Yin","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12902-022-01151-y","article-title":"Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review","volume":"22","author":"Lin","year":"2022","journal-title":"BMC endocrine Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303257557231002064417","article-title":"Hypophysitis induced by sintilimab in the treatment of bladder cancer: A case report","volume":"24","author":"Li","year":"2024","journal-title":"Endocrine Metab Immune Disord Drug targets"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2572-z","article-title":"Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis","volume":"135","author":"Tian","year":"2017","journal-title":"J neuro-oncology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2405562","article-title":"Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars","volume":"24","author":"Seiwerth","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1534179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T01:57:00Z","timestamp":1737597420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1534179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2025.1534179"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1534179","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1534179"}}